University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.

The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.

The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

Columbia's drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.

Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.

Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.